$1.59
0.63% yesterday
Nasdaq, Aug 25, 10:00 pm CET
ISIN
US29479A1088
Symbol
ERAS

Erasca Inc Stock price

$1.59
-0.15 8.62% 1M
+0.19 13.57% 6M
-0.92 36.65% YTD
-1.31 45.17% 1Y
-6.70 80.82% 3Y
-15.84 90.88% 5Y
-15.84 90.88% 10Y
-15.84 90.88% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
-0.01 0.63%
ISIN
US29479A1088
Symbol
ERAS
Industry

Key metrics

Basic
Market capitalization
$453.9m
Enterprise Value
$153.2m
Net debt
positive
Cash
$300.7m
Shares outstanding
283.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.2
Financial Health
Equity Ratio
84.3%
Return on Equity
-38.2%
ROCE
-33.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-135.9m | $-157.9m
EBIT
$-139.2m | $-153.7m
Net Income
$-128.3m | $-128.5m
Free Cash Flow
$-99.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
5.6% | -6.3%
EBIT
5.9% | -0.9%
Net Income
19.0% | 20.5%
Free Cash Flow
11.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
$-0.3
Short interest
7.6%
Employees
103
Rev per Employee
$0.0
Show more

Is Erasca Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Erasca Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Erasca Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Erasca Inc forecast:

Buy
93%
Hold
7%

Financial data from Erasca Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 38 38
3% 3%
-
- Research and Development Expense 101 101
7% 7%
-
-136 -136
6% 6%
-
- Depreciation and Amortization 3.28 3.28
18% 18%
-
EBIT (Operating Income) EBIT -139 -139
6% 6%
-
Net Profit -128 -128
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about Erasca Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Erasca Inc Stock News

Neutral
GlobeNewsWire
13 days ago
Efficient execution accelerated clinical entry of pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Phase 1 monotherapy data for RAS-targeting franchise expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $387 million as of June 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Erasca, In...
Neutral
GlobeNewsWire
3 months ago
Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializin...
Neutral
GlobeNewsWire
3 months ago
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and will also participate in one-on-one investor mee...
More Erasca Inc News

Company Profile

Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.

Head office United States
CEO Jonathan Lim
Employees 103
Founded 2018
Website www.erasca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today